How Evolocumab (Repatha) Affects ALT Levels
Clinical evidence on Repatha's effect on ALT, including data from FOURIER and post-market surveillance. Learn monitoring protocols, expected changes, and when to act on liver enzyme shifts.
How Evolocumab (Repatha) Affects Your Standard Lipid Panel
Evolocumab (Repatha) mainly lowers LDL-C on a lipid panel. Covers trial results, how soon it changes, and limited triglyceride data.
Does Leqvio (Inclisiran) Affect Lp(a)? Clinical Evidence and Monitoring
The Leqvio label reports no Lp(a) result and lists no Lp(a) use. It covers LDL-C, total cholesterol, non-HDL-C and ApoB, plus dosing and monitoring.
Ipamorelin Effect on CMP (Comprehensive Metabolic Panel)
How ipamorelin acetate may affect a comprehensive metabolic panel, including glucose, kidney markers, liver enzymes, and electrolytes, and what is and is not established from current evidence.
How Ipamorelin Affects the Growth Hormone Stimulation Test
Ipamorelin raises GH levels and can confound GH stimulation test results. Learn the mechanism, expected magnitude of GH rise, washout timing, and monitoring protocols.
How Levothyroxine (Synthroid) Affects Free T3 Levels
Levothyroxine is a T4-only medication, but it can raise Free T3 through peripheral conversion. Learn how Synthroid changes Free T3, what the research shows, and when to test.
How Levothyroxine (Synthroid) Affects Reverse T3 Levels
How levothyroxine changes Reverse T3 (rT3), what the rise means physiologically, when rT3 testing is actually useful, and why TSH and free T4 remain the primary monitoring targets during treatment.
How Levothyroxine (Synthroid) Affects TPO Antibodies
Does levothyroxine lower or raise TPO antibodies? Review of clinical evidence on Synthroid's effect on thyroid peroxidase antibodies in Hashimoto's thyroiditis, including trial data, timelines, and monitoring recommendations.
How Metformin Affects eGFR: Kidney Function, Dosing Thresholds, and Monitoring
Metformin does not directly damage the kidneys, but eGFR determines whether it can be safely prescribed. What the FDA thresholds mean, how monitoring should work, and what remains unproven about kidney protection.
How Metformin Affects HbA1c: Expected Reduction, Timeline, and Monitoring
How much will metformin lower A1c in 6 months? Full effect lands by 12 to 16 weeks: about 1.0 to 1.5 percentage points, more if your baseline was high.
Metformin and Vitamin B12: What the Research Shows
Metformin lowers B12 by 10-22% over 1-4 years, with deficiency in 5-10% of long-term users. Learn the mechanism and who needs monitoring.
How Mounjaro Affects Continuous Glucose Monitor (CGM) Readings
Tirzepatide (Mounjaro) is expected to lower CGM glucose and raise time in range within weeks of dose escalation. What is established from trial evidence, what needs primary-source verification, and how to adjust CGM monitoring during titration.
How Mounjaro Affects Your CMP (Comprehensive Metabolic Panel)
Tirzepatide (Mounjaro) can shift multiple CMP markers including fasting glucose, ALT, AST, creatinine, and electrolytes. This article reviews the direction and general magnitude of those changes from published SURPASS trial data, and flags where exact numbers need verification against the primary source.
How Mounjaro (Tirzepatide) Affects eGFR: Kidney Function Changes Explained
Learn how Mounjaro (tirzepatide) affects eGFR and kidney function. Review clinical trial data from SURPASS and SURMOUNT programs, monitoring timelines, and what eGFR changes mean for patients on tirzepatide.
How Mounjaro Affects Fasting Glucose
Tirzepatide (Mounjaro) lowers fasting glucose in type 2 diabetes. See the SURPASS-1 and meal-test data, the mechanism, timing and hypoglycemia risk.
How Mounjaro Affects Fasting Triglycerides
Tirzepatide (Mounjaro) is linked to lower fasting triglycerides in a meta-analysis. See what the evidence shows and what the label covers.
How Oral Micronized Progesterone Affects Progesterone Levels
Oral micronized progesterone (Prometrium) raises serum progesterone in a dose-dependent manner. Learn the expected magnitude, time course, monitoring windows, and clinical implications for HRT.
How Ozempic Affects Continuous Glucose Monitor (CGM) Readings
Semaglutide (Ozempic) is expected to lower mean CGM glucose, reduce glycemic variability, and increase time in range in people with type 2 diabetes. Here is what is established, what is plausible but unconfirmed by verified primary sources, and how to read your own CGM data safely.
How Ozempic Affects HbA1c: Expected Reductions, Timeline, and Monitoring
Ozempic (semaglutide) lowers HbA1c by 1.0 to 1.8 percentage points in clinical trials. Learn the dose-response curve, when to recheck labs, and how it compares to other GLP-1 receptor agonists.
How Ozempic Affects Your Lipid Panel: Cholesterol, Triglycerides, and LDL Changes on Semaglutide
In a US cohort on semaglutide 2.4 mg, mean LDL fell 8.1 mg/dL and triglycerides fell 38.4 mg/dL at 52 weeks, with no significant HDL change.
PT-141 (Bremelanotide) Effect on 24-Hour Ambulatory Blood Pressure
How bremelanotide (PT-141) affects 24-hour ambulatory blood pressure, including magnitude of change, time course, mechanism, and clinical monitoring guidance based on RCT data.
Rosuvastatin and ApoB: What a Lower Result Can Tell You
Learn how to interpret an ApoB result on rosuvastatin, including trial reductions, differences from LDL-C, repeat testing, and limits of outcome evidence.
How Rosuvastatin (Crestor) Affects AST Levels
What rosuvastatin (Crestor) does to AST liver enzymes, how to tell a muscle-source rise from a liver-source rise, current monitoring practice, and when an AST change on this statin needs urgent follow-up.
How Sermorelin Affects IGF-1: Mechanism, Magnitude, and Monitoring
Sermorelin stimulates pituitary GH release. IGF-1 rose in one older-men study and stayed flat in another, with no typical change established.
How Testosterone Cypionate Affects ApoB
Evidence-based guide to testosterone cypionate's effect on apolipoprotein B (ApoB), including direction of change, magnitude, time course, mechanism, and monitoring recommendations.
How Testosterone Cypionate Affects Estradiol (Sensitive)
Testosterone cypionate raises estradiol levels through aromatization. What is established, what is plausible but unproven, and how sensitive-assay monitoring should be timed and interpreted.
How Testosterone Cypionate Affects SHBG Levels
The Depo-Testosterone label gives no SHBG change for testosterone cypionate. Low SHBG in obesity and diabetes can lower total testosterone readings.
How Wegovy Affects ALT: What Semaglutide 2.4 mg Does to Liver Enzymes
Wegovy (semaglutide 2.4 mg) is associated with falling ALT levels in most patients treated for obesity, driven by weight loss and liver fat reduction. This article covers what trial evidence establishes, monitoring, red flags, and when ALT changes need workup.
How Wegovy Affects AST Levels
Semaglutide 2.4 mg (Wegovy) typically lowers AST by reducing hepatic fat. Learn the expected magnitude, time course, monitoring schedule, and when AST changes on Wegovy warrant clinical attention.
How Wegovy Affects DEXA Body Composition: Fat Loss, Lean Mass, and Monitoring
Wegovy (semaglutide 2.4 mg) changes body composition measurably on DEXA. Here is what happens to fat mass, lean mass, and visceral fat, plus when to scan and how to preserve muscle.
How Wegovy Affects eGFR: Renal Effects of Semaglutide 2.4 mg
A guide to how Wegovy (semaglutide 2.4 mg) affects estimated glomerular filtration rate (eGFR), including trial data from STEP-1, FLOW, and SELECT, monitoring timelines, and what eGFR changes mean for patients on GLP-1 therapy.
How Wegovy Affects Your Lipid Panel: Cholesterol, Triglycerides, and LDL Changes on Semaglutide 2.4 mg
Wegovy (semaglutide 2.4 mg) improves multiple lipid panel markers. Learn the direction, magnitude, and timeline of cholesterol and triglyceride changes backed by STEP trial data.
How Zepbound Affects DEXA Body Composition: Lean Mass, Fat Loss, and What Scans Show
Tirzepatide (Zepbound) changes body composition on DEXA scans. Learn how much fat vs. Lean mass is lost, when to schedule scans, and how to protect muscle during treatment.
How Zepbound Affects Visceral Adipose Tissue (VAT)
Tirzepatide (Zepbound) significantly reduces visceral adipose tissue. Learn the clinical data on VAT loss magnitude, timeline, mechanisms, and monitoring from SURMOUNT trials.
Hair Loss Treatment: Prescription Options Ranked (2026)
Finasteride, minoxidil, spironolactone and dutasteride compared by trial data, with dosing, who should avoid each drug, and monitoring schedules.
Leqvio (Inclisiran) Food & Supplement Interactions: What Patients Need to Know
A guide to inclisiran (Leqvio) food and supplement interactions, covering mechanism of action, known drug-nutrient interactions, and practical dietary guidance for patients on twice-yearly PCSK9 siRNA therapy.
Cholesterol Injection Schedules: Twice-Yearly Dosing for Seniors
Inclisiran (Leqvio) is dosed the same for adults 65 and older, and age did not significantly affect its pharmacokinetics in a 4,328-patient analysis.
Leqvio (Inclisiran) Manufacturing, Supply, and Shortage History
A clinical overview of Leqvio (inclisiran) manufacturing processes, supply chain logistics, shortage history, and current availability status for prescribers and patients.
Leqvio Twice-Yearly Dosing Schedule (Official FDA Regimen)
Leqvio dosing is 284 mg at day 0, month 3, then every 6 months for all adults, including ages 50 to 64. No age-based dose adjustment is specified.
Inclisiran (Leqvio) During Pregnancy and Lactation: What the Evidence Actually Shows
A source-checked look at what is and is not known about inclisiran (Leqvio) safety in pregnancy and breastfeeding, based on FDA labeling, animal reproductive toxicology data, and current lipid-management guidelines.
Leqvio (Inclisiran) Regulatory Status: EU and US
EMA authorised Leqvio (inclisiran) in 2020 and the FDA approved it in 2021, with no cardiovascular outcomes result for inclisiran itself yet.
Does TRICARE Cover Leqvio (Inclisiran)? What the Label Says
FDA labeling does not address insurance, so TRICARE coverage of Leqvio cannot be confirmed. This page covers its dosing, labeled uses and safety.
Insulin Cap and IRA Impact: What the $35 Limit Means for Diabetes Costs in 2026
The Inflation Reduction Act capped insulin copays at $35/month for Medicare beneficiaries and triggered private-market price cuts. Here is what the IRA insulin cap covers, what it misses, and how to minimize your total diabetes costs in 2026.
Tresiba Cost vs. Alternatives: Basal Insulin Compared
FDA lists no insulin degludec biosimilar. In DEVOTE, degludec was noninferior to glargine U-100 for heart events, with severe hypoglycemia 4.9% vs 6.6%.
Tresiba Missed-Dose Protocol: What to Do When You Skip Insulin Degludec
Evidence-based guide to managing a missed dose of Tresiba (insulin degludec), including timing rules, clinical pharmacology, and when to contact your provider.
Lantus Adult (30 to 49) Dosing: Insulin Glargine Initiation, Titration, and Optimization
Evidence-based insulin glargine (Lantus) dosing guide for adults aged 30 to 49 with type 1 or type 2 diabetes, including initiation protocols, titration algorithms, and real-world clinical considerations.
How to Safely Stop Lantus (Insulin Glargine): A Clinician-Guided Discontinuation Protocol
Evidence-based guidance on safely tapering or stopping insulin glargine (Lantus), including who qualifies, stepdown protocols, monitoring benchmarks, and when discontinuation is medically inappropriate.
Insulin Glargine (Lantus) Complete Drug-Drug Interaction Profile
A clinician-grade review of every major drug-drug interaction with insulin glargine (Lantus, Basaglar, Semglee, Toujeo), including hypoglycemia potentiators, hyperglycemic antagonists, and masking agents.
Lantus Geriatric (65+) Dosing: Insulin Glargine Dose Adjustments for Older Adults
Evidence-based guide to insulin glargine (Lantus) dosing in adults 65 and older, covering starting doses, titration, hypoglycemia risk, renal adjustments, and deprescribing strategies.
Lantus History and Development: How Insulin Glargine Changed Basal Insulin Therapy
Insulin glargine's A21 glycine and B31-B32 arginine modifications shift the isoelectric point to pH 6.7, causing microprecipitation at physiologic pH 7.4.
Lantus Missed-Dose Protocol: What to Do When You Skip Insulin Glargine
What the Semglee and Rezvoglar labels say about missed insulin glargine doses, how long one injection lasts, and the hypoglycemia risk.
Lantus Storage, Stability & Shelf Life: Complete Insulin Glargine Guide
Does Lantus need refrigerating? Yes: unopened vials and pens keep at 36 to 46 °F until expiry date. Once opened, store at room temp and toss in 28 days.
Adderall XR and Atorvastatin Interaction: What Prescribers and Patients Should Know
A clinical review of the drug interaction between Adderall XR (mixed amphetamine salts) and atorvastatin, covering CYP metabolism, cardiovascular monitoring, and dose-adjustment guidance.
Adderall XR and Hormonal Contraceptives: Drug Interaction Guide
Adderall and birth control: no clinically significant interaction. Amphetamines don't reduce contraceptive efficacy; monitor blood pressure and heart rate.
Adderall XR and Finasteride Interaction: Safety, Mechanisms, and Clinical Guidance
Board-reviewed analysis of the Adderall XR (mixed amphetamine salts) and finasteride drug interaction, covering CYP metabolism, shared side effects, cardiovascular monitoring, and practical prescribing guidance.
Adderall XR and PPIs (Omeprazole, Pantoprazole): Drug Interaction Guide
The Adderall tablet and Nexium labels list no PPI interaction with Adderall. Antacids and sodium bicarbonate carry a separate pH warning.
Adderall XR and Pregabalin Interaction: Safety, Mechanisms, and Clinical Guidance
A pharmacology-based review of the Adderall XR (mixed amphetamine salts) and pregabalin combination, covering mechanism, monitoring, dose timing, and where the evidence runs out.
Adderall XR and SSRIs (Sertraline, Escitalopram): Interaction Risk, Monitoring, and Safety
Clinical guide to combining Adderall XR (mixed amphetamine salts) with SSRIs like sertraline or escitalopram. Covers serotonin syndrome risk, CYP2D6 interactions, dose adjustments, and monitoring.
Adderall XR and Tadalafil Interaction: Risks, Monitoring, and Clinical Guidance
Board-reviewed guide to the mixed amphetamine salts (Adderall XR) and tadalafil drug interaction, covering mechanism, severity, monitoring parameters, and dose-adjustment strategies.
Adderall XR and Testosterone: Interaction Risk, Monitoring, and What to Tell Your Doctor
Board-reviewed guide to the Adderall XR (mixed amphetamine salts) and testosterone interaction. Covers pharmacokinetic overlap, polycythemia risk, cardiovascular monitoring, and dose-adjustment considerations.